2023-05-012024-04-302024-04-30false10555875SINOLINK HEALTHCARE LIMITED2025-01-30falseiso4217:GBPxbrli:pure105558752023-05-01105558752024-04-30105558752023-05-012024-04-30105558752022-05-01105558752023-04-30105558752022-05-012023-04-3010555875bus:SmallEntities2023-05-012024-04-3010555875bus:AuditExempt-NoAccountantsReport2023-05-012024-04-3010555875bus:FullAccounts2023-05-012024-04-3010555875bus:PrivateLimitedCompanyLtd2023-05-012024-04-3010555875core:WithinOneYear2024-04-3010555875core:AfterOneYear2024-04-3010555875core:WithinOneYear2023-04-3010555875core:AfterOneYear2023-04-3010555875core:ShareCapital2024-04-3010555875core:SharePremium2024-04-3010555875core:RevaluationReserve2024-04-3010555875core:OtherReservesSubtotal2024-04-3010555875core:RetainedEarningsAccumulatedLosses2024-04-3010555875core:ShareCapital2023-04-3010555875core:SharePremium2023-04-3010555875core:RevaluationReserve2023-04-3010555875core:OtherReservesSubtotal2023-04-3010555875core:RetainedEarningsAccumulatedLosses2023-04-3010555875core:LandBuildings2024-04-3010555875core:PlantMachinery2024-04-3010555875core:Vehicles2024-04-3010555875core:FurnitureFittings2024-04-3010555875core:OfficeEquipment2024-04-3010555875core:NetGoodwill2024-04-3010555875core:IntangibleAssetsOtherThanGoodwill2024-04-3010555875core:ListedExchangeTraded2024-04-3010555875core:UnlistedNon-exchangeTraded2024-04-3010555875core:LandBuildings2023-04-3010555875core:PlantMachinery2023-04-3010555875core:Vehicles2023-04-3010555875core:FurnitureFittings2023-04-3010555875core:OfficeEquipment2023-04-3010555875core:NetGoodwill2023-04-3010555875core:IntangibleAssetsOtherThanGoodwill2023-04-3010555875core:ListedExchangeTraded2023-04-3010555875core:UnlistedNon-exchangeTraded2023-04-3010555875core:LandBuildings2023-05-012024-04-3010555875core:PlantMachinery2023-05-012024-04-3010555875core:Vehicles2023-05-012024-04-3010555875core:FurnitureFittings2023-05-012024-04-3010555875core:OfficeEquipment2023-05-012024-04-3010555875core:NetGoodwill2023-05-012024-04-3010555875core:IntangibleAssetsOtherThanGoodwill2023-05-012024-04-3010555875core:ListedExchangeTraded2023-05-012024-04-3010555875core:UnlistedNon-exchangeTraded2023-05-012024-04-3010555875core:MoreThanFiveYears2023-05-012024-04-3010555875core:Non-currentFinancialInstruments2024-04-3010555875core:Non-currentFinancialInstruments2023-04-3010555875dpl:CostSales2023-05-012024-04-3010555875dpl:DistributionCosts2023-05-012024-04-3010555875core:LandBuildings2023-05-012024-04-3010555875core:PlantMachinery2023-05-012024-04-3010555875core:Vehicles2023-05-012024-04-3010555875core:FurnitureFittings2023-05-012024-04-3010555875core:OfficeEquipment2023-05-012024-04-3010555875dpl:AdministrativeExpenses2023-05-012024-04-3010555875core:NetGoodwill2023-05-012024-04-3010555875core:IntangibleAssetsOtherThanGoodwill2023-05-012024-04-3010555875dpl:GroupUndertakings2023-05-012024-04-3010555875dpl:ParticipatingInterests2023-05-012024-04-3010555875dpl:GroupUndertakingscore:ListedExchangeTraded2023-05-012024-04-3010555875core:ListedExchangeTraded2023-05-012024-04-3010555875dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-05-012024-04-3010555875core:UnlistedNon-exchangeTraded2023-05-012024-04-3010555875dpl:CostSales2022-05-012023-04-3010555875dpl:DistributionCosts2022-05-012023-04-3010555875core:LandBuildings2022-05-012023-04-3010555875core:PlantMachinery2022-05-012023-04-3010555875core:Vehicles2022-05-012023-04-3010555875core:FurnitureFittings2022-05-012023-04-3010555875core:OfficeEquipment2022-05-012023-04-3010555875dpl:AdministrativeExpenses2022-05-012023-04-3010555875core:NetGoodwill2022-05-012023-04-3010555875core:IntangibleAssetsOtherThanGoodwill2022-05-012023-04-3010555875dpl:GroupUndertakings2022-05-012023-04-3010555875dpl:ParticipatingInterests2022-05-012023-04-3010555875dpl:GroupUndertakingscore:ListedExchangeTraded2022-05-012023-04-3010555875core:ListedExchangeTraded2022-05-012023-04-3010555875dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-05-012023-04-3010555875core:UnlistedNon-exchangeTraded2022-05-012023-04-3010555875core:NetGoodwill2024-04-3010555875core:IntangibleAssetsOtherThanGoodwill2024-04-3010555875core:LandBuildings2024-04-3010555875core:PlantMachinery2024-04-3010555875core:Vehicles2024-04-3010555875core:FurnitureFittings2024-04-3010555875core:OfficeEquipment2024-04-3010555875core:AfterOneYear2024-04-3010555875core:WithinOneYear2024-04-3010555875core:ListedExchangeTraded2024-04-3010555875core:UnlistedNon-exchangeTraded2024-04-3010555875core:ShareCapital2024-04-3010555875core:SharePremium2024-04-3010555875core:RevaluationReserve2024-04-3010555875core:OtherReservesSubtotal2024-04-3010555875core:RetainedEarningsAccumulatedLosses2024-04-3010555875core:NetGoodwill2023-04-3010555875core:IntangibleAssetsOtherThanGoodwill2023-04-3010555875core:LandBuildings2023-04-3010555875core:PlantMachinery2023-04-3010555875core:Vehicles2023-04-3010555875core:FurnitureFittings2023-04-3010555875core:OfficeEquipment2023-04-3010555875core:AfterOneYear2023-04-3010555875core:WithinOneYear2023-04-3010555875core:ListedExchangeTraded2023-04-3010555875core:UnlistedNon-exchangeTraded2023-04-3010555875core:ShareCapital2023-04-3010555875core:SharePremium2023-04-3010555875core:RevaluationReserve2023-04-3010555875core:OtherReservesSubtotal2023-04-3010555875core:RetainedEarningsAccumulatedLosses2023-04-3010555875core:NetGoodwill2022-05-0110555875core:IntangibleAssetsOtherThanGoodwill2022-05-0110555875core:LandBuildings2022-05-0110555875core:PlantMachinery2022-05-0110555875core:Vehicles2022-05-0110555875core:FurnitureFittings2022-05-0110555875core:OfficeEquipment2022-05-0110555875core:AfterOneYear2022-05-0110555875core:WithinOneYear2022-05-0110555875core:ListedExchangeTraded2022-05-0110555875core:UnlistedNon-exchangeTraded2022-05-0110555875core:ShareCapital2022-05-0110555875core:SharePremium2022-05-0110555875core:RevaluationReserve2022-05-0110555875core:OtherReservesSubtotal2022-05-0110555875core:RetainedEarningsAccumulatedLosses2022-05-0110555875core:AfterOneYear2023-05-012024-04-3010555875core:WithinOneYear2023-05-012024-04-3010555875core:Non-currentFinancialInstrumentscore:CostValuation2023-05-012024-04-3010555875core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-05-012024-04-3010555875core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-05-012024-04-3010555875core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-05-012024-04-3010555875core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-05-012024-04-3010555875core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-05-012024-04-3010555875core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-05-012024-04-3010555875core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-05-012024-04-3010555875core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-05-012024-04-3010555875core:Non-currentFinancialInstrumentscore:CostValuation2024-04-3010555875core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-04-3010555875core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-04-3010555875core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-04-3010555875core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-04-3010555875core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-04-3010555875core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-04-3010555875core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-04-3010555875core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-04-3010555875core:Non-currentFinancialInstrumentscore:CostValuation2023-04-3010555875core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-04-3010555875core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-04-3010555875core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-04-3010555875core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-04-3010555875core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-04-3010555875core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-04-3010555875core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-04-3010555875core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-04-3010555875bus:Director12023-05-012024-04-30

SINOLINK HEALTHCARE LIMITED

Registered Number
10555875
(England and Wales)

Unaudited Financial Statements for the Year ended
30 April 2024

SINOLINK HEALTHCARE LIMITED
Company Information
for the year from 1 May 2023 to 30 April 2024

Director

DONG, Mingming

Registered Address

16 Station Approach
Virginia Water
GU25 4DW

Registered Number

10555875 (England and Wales)
SINOLINK HEALTHCARE LIMITED
Statement of Financial Position
30 April 2024

Notes

2024

2023

£

£

£

£

Current assets
Debtors199,980159,581
Cash at bank and on hand-1,983
199,980161,564
Creditors amounts falling due within one year3(77,562)(100,836)
Net current assets (liabilities)122,41860,728
Total assets less current liabilities122,41860,728
Creditors amounts falling due after one year4(17,410)(27,504)
Net assets105,00833,224
Capital and reserves
Called up share capital11
Profit and loss account105,00733,223
Shareholders' funds105,00833,224
The financial statements were approved and authorised for issue by the Director on 30 January 2025, and are signed on its behalf by:
DONG, Mingming
Director
Registered Company No. 10555875
SINOLINK HEALTHCARE LIMITED
Notes to the Financial Statements
for the year ended 30 April 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Current taxation
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Financial instruments
Financial assets and liabilities are recognised in the balance sheet when the company becomes party to the contractual provisions of the instrument. Trade and other debtors and creditors are classified as basic financial instruments and are measured on initial recognition at transaction price. Debtors and creditors are subsequently measured at amortised cost using the effective interest rate method. A provision is established when there is objective evidence that the company not be able to collect all amounts due. Cash and cash equivalents are classified as basic financial instruments and comprise cash in hand and at bank and bank overdrafts which are an integral part of the company's cash management. Financial liabilities and equity instruments issued by the company are classified in accordance with the substance of the contractual arrangements entered into and the definitions of a financial liability and an equity instrument. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Equity instruments issued by the company are recorded at the proceeds received, net of any direct issue costs. Interest bearing bank loans, overdrafts and other loans which meet the criteria of basic financial instruments are initially recorded at the present value of cash payable to the bank, usually being equivalent to the proceeds received net of direct issue costs. These liabilities are subsequently measured at amortised cost, using the effective interest rate method.
2.Average number of employees

20242023
Average number of employees during the year11
3.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables50,34910,979
Bank borrowings and overdrafts15,1399,996
Amounts owed to related parties6360,113
Taxation and social security1668,639
Other creditors10,0449,309
Accrued liabilities and deferred income1,8011,800
Total77,562100,836
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
4.Creditors: amounts due after one year

2024

2023

££
Bank borrowings and overdrafts17,41027,504
Total17,41027,504
5.Related party transactions
Included within other creditors as at 30 April 2024 is an amount of £63 (2023 - £60,113) which is owed to the parent company, Sinolink Limited. Included within other creditors as at 30 April 2024 is an amount of £320 (2023 - Nil) which is owed to Sinolink Healthcare Limited, a company owned by the parent company.